Every 10-Q that IQVIA Holdings Inc. (IQV) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow IQV and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full IQV filings page.
IQVIA Holdings Inc. reported Q2 2026 revenues of $4,368 million, up 8.7% year over year, with income from operations flat at $506 million. Net income attributable to IQVIA was $256 million and diluted EPS was $1.53. For the first half, revenues reached $8,519 million and diluted EPS was $3.14.
Commercial Solutions grew Q2 revenue 8.6% to $1,793 million and segment profit 10.6% to $419 million, while Research & Development Solutions grew revenue 8.8% to $2,575 million and profit 11.2% to $526 million. Contracted R&D backlog was $34.2 billion, with $9.2 billion expected to convert within 12 months, and remaining performance obligations totaled $36.4 billion.
Operating cash flow for the first half was $1,176 million. Cash and cash equivalents were $1,909 million against principal debt of $16,081 million. The company repurchased 5.5 million shares for $950 million and increased its total repurchase authorization to $15,725 million, with $2,819 million remaining.
IQVIA Holdings Inc. reports first-quarter 2026 results with revenues of $4,151 million, up 8.4% from 2025. Net income attributable to IQVIA rose to $274 million, and diluted earnings per share increased to $1.61 from $1.40.
Commercial Solutions revenue grew to $1,754 million, while Research & Development Solutions reached $2,397 million. Operating cash flow was strong at $618 million, supporting capital spending, acquisitions and $552 million of share repurchases. Total debt stood at $15,908 million with access to additional revolving credit capacity.
IQVIA Holdings Inc. reported third‑quarter results with steady growth and active balance sheet management. Q3 2025 revenue was $4.1 billion versus $3.896 billion a year ago, and diluted EPS was $1.93 compared with $1.55. Segment revenue reached $1.631 billion in Technology & Analytics Solutions, $2.260 billion in Research & Development Solutions, and $209 million in Contract Sales & Medical Solutions. Q3 income from operations was $553 million. For the first nine months, revenue totaled $11.946 billion and diluted EPS was $4.86.
Operating cash flow for the nine months was $1.919 billion, supporting $1.032 billion of share repurchases (6.4 million shares). The company issued $2.0 billion of 6.250% senior notes due 2032 and amended its credit facilities, including a $1.985 billion Term B-5 loan to refinance prior tranches. Total debt principal was $15.034 billion and cash was $1.814 billion at quarter‑end. Remaining performance obligations were $34.4 billion, with about 30% expected to convert within 12 months. Goodwill increased to $15.948 billion, reflecting acquisitions. Common shares outstanding were 170.3 million as of October 20, 2025. Legal disputes with Veeva were fully resolved in August 2025 with no payment by either party.